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Dawid Panek 1,†, Anna Więckowska 1,† ID , Anna Pasieka 1, Justyna Godyń 1, Jakub Jończyk 1,
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Abstract: The complex nature of Alzheimer’s disease calls for multidirectional treatment.
Consequently, the search for multi-target-directed ligands may lead to potential drug candidates.
The aim of the present study is to seek multifunctional compounds with expected activity
against disease-modifying and symptomatic targets. A series of 15 drug-like various substituted
derivatives of 2-(benzylamino-2-hydroxyalkyl)isoindoline-1,3-diones was designed by modification
of cholinesterase inhibitors toward β-secretase inhibition. All target compounds have been
synthesized and tested against eel acetylcholinesterase (eeAChE), equine serum butyrylcholinesterase
(eqBuChE), human β-secretase (hBACE-1), and β-amyloid (Aβ-aggregation). The most promising
compound, 12 (2-(5-(benzylamino)-4-hydroxypentyl)isoindoline-1,3-dione), displayed inhibitory
potency against eeAChE (IC50 = 3.33 µM), hBACE-1 (43.7% at 50 µM), and Aβ-aggregation (24.9%
at 10 µM). Molecular modeling studies have revealed possible interaction of compound 12 with the
active sites of both enzymes—acetylcholinesterase and β-secretase. In conclusion: modifications of
acetylcholinesterase inhibitors led to the discovery of a multipotent anti-Alzheimer’s agent, with
moderate and balanced potency, capable of inhibiting acetylcholinesterase, a symptomatic target, and
disease-modifying targets: β-secretase and Aβ-aggregation.
Keywords: isoindoline-1,3-dione derivatives; cholinesterase inhibitors; BACE-1 inhibitors;
Aβ-aggregation; molecular modeling; multiple anti-Alzheimer’s ligands
1. Introduction
Alzheimer’s disease (AD) is one of the neurodegenerative diseases and the most commonly
diagnosed cause of dementia in the elderly. It affects an estimated 36 million people worldwide,
and this figure is expected to increase to 100 million by the end of 2050 [1]. The lack of an effective
disease-modifying treatment for AD, caused, among others, by the disease’s poorly understood
and complex etiopathogenesis, is a major challenge facing modern medicine. Deposits of insoluble
proteins: β-amyloid (Aβ) and hyperphosporylated tau are regarded as the primary cause of
AD. Aβ is the product of enzymatic cleavage of amyloid precursor protein (APP) by β-secretase
(BACE-1) and γ-secretase. Various forms of Aβ, primarily Aβ1–42 and Aβ1–40, have the ability to
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aggregate and create extracellular neurotoxic senile plaques [2]. In parallel, inside neurons, excessive
phosphorylation of the tau protein leads to the formation of neurofibrillary tangles [3]. Both processes
may begin up to 25 years before initial symptoms occur [4]. As complementary elements of the
etiopathogenesis of AD, they represent obvious biological targets in search for anti-AD treatments.
Progressive neurodegeneration in the course of AD affects mainly cholinergic neurotransmission [5–7].
Current pharmacotherapy of AD is therefore based on the restoration of cholinergic activity with
cholinesterase inhibitors: donepezil, rivastigmine, and galantamine. These drugs do not prevent,
reverse, or even slow down the neurodegenerative processes, but offer only symptomatic treatment
based on improving cognition and memory [8]. Therefore, the overriding objective for researchers
is to find new, effective disease-modifying agents for the treatment of AD. Complex diseases,
such as AD, require multidirectional treatment. An interesting form of polypharmacology involves
multi-target-directed-ligands (MTDLs), which are compounds that act on two or more biological targets
and mechanisms [9]. This approach has developed intensively over the last few years, particularly in
the context of multifactorial diseases such as AD [10–13]. A large number of potential multifunctional
anti-AD molecules has been designed and synthesized by combining chemical fragments responsible
for interaction with desirable biological targets [14–18]. In this paper, we present the design, synthesis,
biological evaluation, and molecular modeling studies of new phthalimide derivatives linked by a
hydroxyalkyl chain with a benzylamine moiety, as novel, potential, multifunctional anti-AD agents.
Biological profiling of these new compounds includes the assessment of acetylcholinesterase from
Electrophorus electricus (eeAChE), butyrylcholinesterase from equine serum (eqBuChE), BACE-1, and Aβ
aggregation inhibition.
2. Results and Discussion
2.1. Design
Our main area of interest is the development of new, multifunctional compounds which target
the causes of AD. Previously, we have reported a series of dual binding site donepezil-based inhibitors
of AChE with anti-Aβ aggregating properties. Compound III (Figure 1) was found to be a potent
and selective human AChE inhibitor (IC50 = 0.268 µM) with anti-Aβ aggregation activity (66% at
10 µM) and a neuroprotective effect against Aβ toxicity at 1 µM and 3 µM [19]. Molecular modeling
studies revealed that the phthalimide fragment of compound III is responsible for interactions with
the peripheral anionic site (PAS), while the benzylamine moiety interacts with the catalytic anionic
site of AChE. The goal of the presented study was modification of lead III to introduce additional
inhibitory activity toward BACE-1. A 2-(benzylamino)ethan-1-ol fragment is frequently incorporated
in potent BACE-1 inhibitors; among others, NVP-BXD552 (I) [20] and GRL-8234 (II) [21] (Figure 1).
Therefore, we introduced a hydroxyl group in the alkyl chain of compound III and assumed that the
resulting hydroxyethylamine fragment will mediate interaction with the catalytic dyad of BACE-1
(composed of two aspartic residues: Asp32 and Asp228), which is the key to the effective inhibition of
BACE-1. Moreover, we calculated the most important physicochemical parameters for the designed
compounds and confirmed that they meet the criteria set by Lipinski’s rule of five [22] and possess
drug-like properties.
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different linker lengths based on results of molecular modeling. The general procedure for the 
synthesis of the final compounds (1–15) is presented in Scheme 1. Alkylation of potassium 
phthalimide by ω-bromobut-1-ene derivatives and subsequent oxidation with 
meta-chloroperoxybenzoic acid (mCBPA) yielded epoxides (20–23). These epoxides were then used 
as alkylating agents in a reaction with the appropriate benzylamines, leading to final compounds (1–
15) in their racemic form. 
 
Scheme 1. Synthesis of compounds 1–15. Reagents and conditions: (i) alkenyl halide, DMF, 80 °C, 16 h; 
(ii) meta-chloroperoxybenzoic acid, DCM, room temperature (R.T.) 16 h; (iii) benzylamine 
derivatives, n-propanol, pyridine, 97 °C. 
2.3. Biological Evaluation 
Target compounds 1–15 were subjected to biological screening to test their inhibitory activity 
against acetyl- and butyrylcholinesterase, β-secretase, and aggregation of Aβ. We evaluated the 
potency of the compounds against cholinesterases in Ellman’s assay [23] using AChE from 
Electrophorus electricus (eeAChE) and BuChE from equine serum (eqBuChE). We used tacrine and 
donepezil as reference compounds. Following initial screening at 10 μM, we determined IC50 values 
for compounds which exhibited potency greater than 50%. Eleven out of the fifteen compounds 
display percentages of inhibition of eeAChE between <10% and 33% at a concentration of 10 μM 
(Table 1). Similarly, fourteen out of the fifteen compounds display % inhibition of eqBuChE between 
<10% and 36% at a concentration of 10 μM. Four compounds exhibit moderate eeAChE activity (low 
micromolar IC50) and one compound exhibits moderate eqBuChE inhibitory (low micromolar IC50). 
The most potent AChE inhibitors, with IC50 ranging from 1.95 to 11.07 μM, were compounds 12–15 
Figure 1. Design strategy for multitarget anti-Alzhei er’s agents. CAS: catalytic anionic site, PAS:
peripheral anionic site.
2.2. Chemistry
We synthesized 15 derivatives with various substituents in the benzylamine fragment and different
linker lengths based on results of molecular modeling. The general procedure for the synthesis
of the final compounds (1–15) is presented in Scheme 1. Alkylation of potassium phthalimide by
ω-bromobut-1-ene derivatives and subsequent oxidation with meta- loroperoxybenzoic acid (mCBPA)
yielded epoxides (20–23). These epoxides were then used as alkylating agents in a reaction with the
appropriate benzylamines, leading to final compounds (1–15) in their racemic form.
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Scheme 1. Synthesis of compounds 1–15. Reagents and conditions: (i) alkenyl halide, DMF, 80 ◦C, 16 h;
(ii) meta-chloroperoxybenzoic acid, DCM, room temperature (R.T.) 16 h; (iii) benzylamine derivatives,
n-propanol, pyridine, 97 ◦C.
2.3. Biological Evaluation
Target compounds 1–15 were subjected to biological screening to test their inhibitory activity
against acetyl- and but ylcholinesterase, β-secretase, and aggregation of Aβ. We evaluated the
potency of the compounds against cholinesterases in Ellman’s assay [23] using AChE from Electrophorus
electricus (eeAChE) and BuChE from equine serum (eqBuChE). We used tacrine and donepezil as
reference compounds. Following initial screening at 10 µM, we determined IC50 values for compounds
which exhibited potency great r than 50%. Eleven ut of the fifteen compound display percen ages
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of inhibition of eeAChE between <10% and 33% at a concentration of 10 µM (Table 1). Similarly,
fourteen out of the fifteen compounds display % inhibition of eqBuChE between <10% and 36%
at a concentration of 10 µM. Four compounds exhibit moderate eeAChE activity (low micromolar
IC50) and one compound exhibits moderate eqBuChE inhibitory (low micromolar IC50). The most
potent AChE inhibitors, with IC50 ranging from 1.95 to 11.07 µM, were compounds 12–15 with longer
3- and 4-carbon atom linkers. This observation is similar to our previous findings [19] concerning
phthalimide-benzylamine derivatives as cholinesterase inhibitors (compound III). The optimal linker
length, ensuring interaction with both catalytic anionic site CAS and PAS, was five carbon atoms
(compound III), corresponding to n = 3 in compounds discussed in this work. Compounds with
shorter linkers (n = 1 and n = 2) are weak inhibitors of eeAChE (11.5–32.7% inhibition at 10 µM),
or are altogether inactive (<10% inhibition). We have not observed any structure-activity relationship
regarding substituents at the benzylamine ring; however, we only synthesized differently substituted
derivatives with the shortest linkers. Regarding inhibition of eqBuChE, we found compound 5,
for which we determined the IC50 value (7.86 µM). Unlike the case of AChE inhibition, the most
potent inhibitor of BuChE was those compounds with shorter carbon linkers (n = 1). Comparing the
unsubstituted benzylamine derivative with the 2-methoxy substituted one (1 versus 5) we conclude
that this substitution is important for BuChE inhibitory activity. The results obtained show that
introduction of the hydroxyl group to the alkyl chain led to a reduction in inhibitory activity with
respect to both cholinesterase compared to the model compound III.
To determine the inhibitory activity of the reported compounds against human recombinant
BACE-1 (hBACE-1), we used a biochemical spectrofluorometric assay (fluorescence resonance energy
transfer, FRET-based) [24,25]. The assay is based on the cleavage of an amyloid precursor protein
APP analogue with the Swedish mutation, leading to an increase in fluorescence. As a reference, we
included inhibitor IV and established its IC50 value at 46 nM, which is in accordance with published
data [26]. We tested each compound at 50 µM concentrations and calculated their inhibitory activity,
which ranged from 15.7% for 15 to 45.0% for 6 (Table 1).
We determined Aβ antiaggregating properties for the presented compounds (1–15) in a
thioflavin-T assay [27]. The assay was performed at 10 µM inhibitor concentration. Donepezil was
used as the reference, since the presented compounds had been structurally developed from this drug.
We also included resveratrol as a much stronger inhibitor of Aβ aggregation (Table 1). We found
that three of the tested compounds significantly inhibit Aβ aggregation: 2, 5, and 12, with inhibition
percentages of 21.1%, 19.9%, and 24.9%, respectively (at 10 µM) (Figure 2). These results are inferior to
resveratrol but superior to donepezil.
Molecules 2018, 23, x  4 of 15 
 
with long r 3- nd 4-carbon ato  li ke s. This bs rvation is similar to our previous findings [19] 
concerning phthalimide-benzylamine derivatives as cholinesterase inhibitors (compound III). The 
optimal linker length, ensuring interaction with both catalytic anionic site CAS and PAS, was five 
carbon atoms (compound III), corresponding to n = 3 in compounds discussed in this work. 
Compounds with shorter linkers (n = 1 and n = 2) are weak inhibitors of eeAChE (11.5–32.7% 
inhibitio  at 10 μM), or are altogether inactive (<10% inhibition). We hav  not ob erved any 
structure-activity relationship regarding substituents at the benzylamine ring; however, we only 
synthesized differently substituted derivatives with the shortest linkers. Regarding inhibition of 
eqBuChE, we found compound 5, for which we determined the IC50 value (7.86 μM). Unlike the case 
of AChE inhibition, the most potent inhibitor of BuChE was those compounds with shorter carbon 
linkers (n = 1). Comparing the unsubstituted b nzylamine derivative with the 2-methoxy substituted 
one (1 versus 5) we conclude that this substitution is important for BuChE inhibitory activity. The 
results obtained show that introduction of the hydroxyl group to the alkyl chain led to a reduction in 
inhibitory activity with respect to both cholinesterase compared to the model compound III. 
To determine the inhibitory activity of the reported compounds against human recombinant 
BACE-1 (hBACE-1), we used a biochemical spectrofluorometric assay (fluorescence r sonance 
energy transfer, FRET-based) [24,25]. The assay is based on the cleavage of an amyloid precursor 
protein APP analogue with the Swedish mutation, leading to an increase in fluorescence. As a 
reference, we included inhibitor IV and established its IC50 value at 46 nM, which is in accordance 
with published data [26]. We tested each compound at 50 μM concentrations and calculated their 
inhibitory activity, which ranged from 15.7% for 15 o 45.0% for 6 (Table 1). 
We determined Aβ antiaggregating properties for the presented compounds (1–15) in a 
thioflavin-T assay [27]. The assay was performed at 10 μM inhibitor concentration. Donepezil was 
used as the reference, since the presented compounds had been structurally developed from this 
drug. We also included resveratrol as a much stronger inhibitor of Aβ aggregation (Table 1). We 
found that three of the tested compounds significantly inhibit Aβ aggregation: 2, 5, and 12, with 
inhibition percentages of 21.1%, 19.9%, and 24.9%, respectively (at 10 μM) (Figure 2). These results 
are inferior to resveratrol but superior to donepezil. 
 
Figure 2. Effect of the synthesized compounds on Aβ aggregation. Values are expressed as means ± 
standard deviation (SD) for at least two independent experiments 
  
0
20
40
60
80
100
control resveratrol donepezil 2 5 12
%Aβ-aggr.
Aβ-aggregation Compound
Figure 2. Effect of th synt esized compounds on A gregation. Valu s are express d as means ±
standard deviation (SD) for at least two independent experiments.
Molecules 2018, 23, 347 5 of 15
Table 1. Inhibitory activity on eeAChE, eqBuChE, hBACE-1, and Aβ for the presented compounds.
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6 4-Me 1 <10% 11.6 ± 3.3% 45.0% ± 2.0% <10%
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2.4. Molecular Modeling Studies
The presented active compounds were docked into the Torpedo californica AChE crystal structure,
as well as into human BuChE and human BACE-1. Docking was performed in order to determine
the causes of potency variations, by finding differences in the potential bonding mode. We used
previously developed methods to dock ligands and assess the binding modes [28,29]. In the case of
AChE, the length of the li ker had a significant influence on ligand arrangement in the e zymatic active
gorge and on docking score value (from 34.01 for inactive compound 3 to 44.47 for active compound
14. The presence of a h droxyl group within the linker made it very difficult for the compounds to
adjust to the AChE active site. Short linkers (n = 1 and n = 2) were halted within the PAS by hydrogen
bonds generated by OH with Tyr334 and Asp72, restricting interactions between benzylamine and
CAS or between phthalimide and PAS. As the linker grows in length, the effect of the hydroxyl group
is compensated for by the flexibility of the compound. The binding mode of the most active inhibitor
15 is shown in Figure 3.
Despite hydrogen bonding of the hydroxyl group with Tyr334 and Asp72 at the proximal part of
the active gorge, this compound ad pts a conformation which res mbles potent donepezil-like AChE
inhibitors. The first key element, is the benzylamine position, p ov ding CH-π interaction with Trp84
and cation-π interactions with Phe330. Hydrogen bonds between the ligand and the conserved water
molecule (1159) appear to be significant. The most active compound, with the longest carbon linker,
also provides the best phthalimide-PAS fit. This was the only compound which formed both hydrogen
bonds, with Tyr121 and conserved water molecule (1254), while maintaining optimal π-π interaction
with Trp279 and CH-π interaction with Tyr-70.
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Despite the addition of a hydroxyethylamine moiety associated with the benzyl substituent, which
is a characteristic pharmacophore in BACE-1 inhibitors, the tested compounds did not exhibit strong
enzymatic inhibition potency. Molecular modeling studies indicate that the described pharmacophore
binds at the preferred place (catalytic dyad consisting of Asp32 and Asp221); however, there is a
very broad variation in the predicted conformation of both aromatic systems. The good fit of the
phthalimide fragment within the S3 hydrophobic pocket makes it difficult to direct the benzylic
substituent towards the S2′ pockets. This situation is illustrated in Figure 5. Compound 6 showed
the highest-rated conformation in the BACE-1 active site. In other conformations obtained during
docking experiments, the benzylamine and hydroxyethyl moieties assumed the same position as the
corresponding reference compound (NVP-BXD552); however, under these conditions phthalimide
provides only weak interaction beyond the S3 sub-pocket.
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used without further purification. The following compounds: 2-allylisoindoline-1,3-dione (16) [31],
2-(but-3-en-1-yl)isoindoline-1,3-dione (17) [32], 2-(pent-4-en-1-yl)isoindoline-1,3-dione (18) [33],
2-(hex-5-en-1-yl)isoindoline-1,3-dione (19) [34], 2-(oxiran-2-ylmethyl)isoindoline-1,3-dione (20) [35],
2-(2-(oxiran-2-yl)ethyl)isoindoline-1,3-dione (21) [35], 2-(3-(oxiran-2-yl)propyl)isoindoline-1,3-dione
(22) [35], 2-(4-(oxiran-2-yl)butyl)isoindoline-1,3-dione (23) [36] have been reported previously.
3.1.2. General Procedure for the Synthesis of Compounds: 1–15 (Procedure A)
2-(ω-(oxiranyl)alkyl)isoindoline-1,3-dione (21) (1.0 equiv.), corresponding benzylamine (1.0
equiv.), and a catalytic amount of pyridine in n-propanol were refluxed for 16 h. Then, the solvent was
evaporated and the resulting residue was purified by flash column chromatography using a mixture
of MeOH and DCM (gradient from 1% to 10% of MeOH).
2-(3-(Benzylamino)-2-hydroxypropyl)isoindoline-1,3-dione (1). Following the procedure A, reaction of
phenylmethanamine (0.065 mL, 0.591 mmoL) with 2-(oxiran-2-ylmethyl)isoindoline-1,3-dione (20)
(0.120 g, 0.591 mmoL) and a catalytic amount of pyridine in 4 mL n-propanol was performed. Yield:
36 mg (19.6%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.33. MW 310.35. Formula C18H18N2O3. MS m/z
311.09 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.80–7.89 (m, 2H), 7.66–7.76 (m, 2H), 7.18–7.38 (m,
5H), 3.98 (tdd, J = 6.92, 5.26, 3.98 Hz, 1H), 3.69–3.87 (m, 4H), 2.79 (dd, J = 12.31, 3.85 Hz, 1H), 2.65
(dd, J = 12.31, 7.18 Hz, 1H), 2.33 (br.s., 2H). 13C NMR (75 MHz, CDCl3) δ 168.67, 139.62, 134.05, 131.97,
128.47, 128.14, 127.16, 123.38, 68.05, 53.75, 51.84, 41.91.
2-(3-((2-Fluorobenzyl)amino)-2-hydroxypropyl)isoindoline-1,3-dione (2). Following the procedure A, reaction
of (2-fluorophenyl)methanamine (0.068 mL, 0.591 mmoL) with 2-(oxiran-2-ylmethyl)isoindoline-1,3-dione
(20) (0.120 g, 0.591 mmoL) and a catalytic amount of pyridine in 4 mL n-propanol was performed. Yield:
50 mg (26.0%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.21. MW 328.34. Formula C18H17FN2O3. MS m/z
329.10 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.79–7.88 (m, 2H), 7.66–7.75 (m, 2H), 7.35 (td, J = 7.50,
1.67 Hz, 1H), 7.19–7.29 (m, 1H), 7.06–7.14 (m, 1H), 7.02 (ddd, J = 10.00, 8.46, 1.03 Hz, 1H), 3.98–4.10
(m, 1H), 3.90 (s, 2H), 3.81 (dd, J = 14.11, 6.92 Hz, 1H), 3.73 (dd, J = 13.85, 4.87 Hz, 1H), 3.49 (br.s., 2H),
2.81 (dd, J = 12.31, 3.85 Hz, 1H), 2.66 (dd, J = 12.05, 7.44 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 168.03,
162.21, 133.44, 131.35, 129.99 (d, JC=F = 1.9 Hz), 128.60 (d, JC=F = 8.29 Hz), 125.04 (d, JC=F = 14.93 Hz),
123.61 (d, JC=F = 3.32 Hz), 122.78, 114.78 (d, JC=F = 22.12 Hz), 67.11, 50.97, 46.23, 41.23.
2-(2-Hydroxy-3-((2-(trifluoromethyl)benzyl)amino)propyl)isoindoline-1,3-dione (3). Following the procedure A,
reaction of (2-(trifluoromethyl)phenyl)methanamine (0.270 mL, 1.969 mmoL) with 2-(oxiran-2-ylmethyl)
isoindoline-1,3-dione (20) (0.400 g, 1.969 mmoL) and a catalytic amount of pyridine in 5 mL n-propanol
was performed. Yield: 150 mg (20.1%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.16. MW 378.35.
Formula C19H17F3N2O3. MS m/z 379.08 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.81–7.90 (m, 2H),
7.69–7.77 (m, 2H), 7.62 (t, J = 8.50 Hz, 2H), 7.52 (t, J = 7.40 Hz, 1 H), 7.35 (t, J = 7.20 Hz, 1H), 3.94–4.05
(m, 3H), 3.85 (dd, J = 14.11, 6.67 Hz, 1H), 3.77 (dd, J = 13.85, 5.13 Hz, 1H), 2.83 (dd, J = 12.05, 4.10 Hz,
1H), 2.68 (dd, J = 12.05, 7.18 Hz, 1H), 2.23 (br.s., 2H) 13C NMR (75 MHz, CDCl3) δ 168.70, 138.43 (d, JC=F
= 1.11 Hz), 134.08, 132.11, 130.31, 128.50, 127.08, 126.28, 125.94 (JC=F = 6.08 Hz), 123.40, 122.64, 68.25,
52.14, 49.84 (d, JC=F = 2.21 Hz), 41.89.
2-(3-((3-Chlorobenzyl)amino)-2-hydroxypropyl)isoindoline-1,3-dione (4). Following the procedure A, reaction
of (3-chlorophenyl)methanamine (0.090 mL, 0.738 mmoL) with 2-(oxiran-2-ylmethyl)isoindoline-1,3-dione
(20) (0.150 g, 0.738 mmoL) and a catalytic amount of pyridine in 4.5 mL n-propanol was performed. Yield:
75 mg (29.5%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.22. MW 344.80. Formula C18H17ClN2O3. MS m/z
345.62 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.81–7.89 (m, 2H), 7.69–7.77 (m, 2H), 7.28–7.33 (m,
1H), 7.14–7.28 (m, 3H), 3.93–4.05 (m, 1H), 3.71–3.89 (m, 4H), 2.77 (dd, J = 12.31, 3.85 Hz, 1H), 2.64
(dd, J = 12.31, 6.92 Hz, 1H), 2.31 (br.s., 2H). 13C NMR (75 MHz, CDCl3) δ 168.72, 141.99, 134.28, 134.10,
131.92, 129.69, 128.16, 127.24, 126.17, 123.41, 68.30, 53.26, 51.88, 41.91.
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2-(2-Hydroxy-3-((2-methoxybenzyl)amino)propyl)isoindoline-1,3-dione (5). Following the procedure A, reaction
of (2-methoxyphenyl)methanamine (0.096 mL, 0.738 mmoL) with 2-(oxiran-2-ylmethyl)isoindoline-1,3-
dione (20) (0.150 g, 0.738 mmoL) and a catalytic amount of pyridine in 4.5 mL n-propanol was performed.
Yield: 66 mg (26.3%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.29. MW 340.38. Formula C19H20N2O4.
MS m/z 341.12 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.83–7.99 (m, 2H), 7.57–7.71 (m, 2H), 7.15–7.23
(m, 1H), 7.09 (dd, J = 7.57, 1.41 Hz, 1H), 6.80–6.89 (m, 2H), 3.80–4.11 (m, 7H), 3.63–3.72 (m, 1H), 3.57
(dd, J = 11.03, 4.62 Hz, 1H), 2.62–3.01 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 167.52, 156.76, 132.98,
132.80, 131.94, 129.72, 128.32, 128.19, 125.44, 123.79, 120.54, 110.58, 70.78, 64.58, 55.61, 52.12, 36.79.
2-(2-Hydroxy-3-((4-methylbenzyl)amino)propyl)isoindoline-1,3-dione (6). Following the procedure A, reaction
of (4-(methyl)phenyl)methanamine (0.063 mL, 121.18 mmoL) with 2-(oxiran-2-ylmethyl)isoindoline-1,3-
dione (20) (0.100 g, 0.492 mmoL) and a catalytic amount of pyridine in 3.5 mL n-propanol was performed.
Yield: 47 mg (29.5%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.22. MW 324.38. Formula C19H20N2O3.
MS m/z 325.11 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.78–7.89 (m, 2H), 7.68–7.72 (m, 2H), 7.06–7.21
(m, 4H), 3.93–4.03 (m, 1H), 3.63–3.86 (m, 4H), 3.00 (br.s., 2H), 2.76 (dd, J = 12.31, 3.85 Hz, 1H), 2.62 (dd,
J = 12.31, 7.44 Hz, 1H), 2.30 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 168.64, 136.75, 136.48, 134.01, 131.97,
129.15, 128.14, 123.35, 67.93, 53.41, 51.79, 41.92, 21.07.
2-(2-Hydroxy-3-((4-methoxybenzyl)amino)propyl)isoindoline-1,3-dione (7). Following the procedure A, reaction
of (4-methoxyphenyl)methanamine (0.096 mL, 0.738 mmoL) with 2-(oxiran-2-ylmethyl)isoindoline-1,3-
dione (20) (0.150 g, 0.738 mmol) and a catalytic amount of pyridine in 4.5 mL n-propanol was performed.
Yield: 92 mg (36.6%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.27. MW 340.38. Formula C19H20N2O4.
MS m/z 341.13 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.79–7.87 (m, 2H), 7.66–7.75 (m, 2H), 7.21–7.27
(m, 2H), 6.80–6.88 (m, 2H), 4.01 (ddd, J = 7.05, 3.46, 1.54 Hz, 1H), 3.66–3.85 (m, 7H), 3.09 (br.s., 2H),
2.79 (dd, J = 12.57, 3.85 Hz, 1H), 2.64 (dd, J = 12.31, 7.44 Hz, 1H) 13C NMR (75 MHz, CDCl3) δ 168.63,
158.85, 134.02, 131.96, 131.05, 129.54, 123.35, 113.89, 67.75, 55.24, 52.95, 51.58, 41.88.
2-(3-((2,4-Dichlorobenzyl)amino)-2-hydroxypropyl)isoindoline-1,3-dione (8). Following the procedure A, reaction
of (2,4-dichlorophenyl)methanamine (0.083 mL, 0.615 mmoL) with 2-(oxiran-2-ylmethyl)isoindoline-1,3-
dione (20) (0.125 g, 0.615 mmol) and a catalytic amount of pyridine in 4.0 mL n-propanol was performed.
Yield: 72 mg (31.4%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.25. MW 379.24. Formula C18H16Cl2N2O3.
MS m/z 379.01, 380.00 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.79–7.88 (m, 2H), 7.68–7.76 (m, 2H),
7.35 (d, J = 2.05 Hz, 1H), 7.30 (d, J = 8.21 Hz, 1H), 7.19 (dd, J = 8.46, 2.31 Hz, 1H), 4.00 (tdd, J = 6.89,
6.89, 5.19, 4.10 Hz, 1H), 3.84–3.88 (m, 2H), 3.75–3.82 (m, 2H), 2.76 (dd, J = 12.57, 3.85 Hz, 1H), 2.63
(dd, J = 12.31, 6.92 Hz, 1H) 2.52 (br.s., 2H) 13C NMR (75 MHz, CDCl3) δ 168.69, 135.86, 134.40, 134.09,
133.43, 131.91, 130.80, 129.33, 127.10, 123.40, 68.24, 51.83, 50.57, 41.91.
2-(4-(Benzylamino)-3-hydroxybutyl)isoindoline-1,3-dione (9). Following the procedure A, reaction of
phenylmethanamine (0.071 mL, 0.650 mmoL) with 2-(2-(oxiran-2-yl)ethyl)isoindoline-1,3-dione (21)
(0.140 g, 0.650 mmoL) and a catalytic amount of pyridine in 4 mL n-propanol was performed. Yield:
55.2 mg (26.2%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.18. MW 324.38. Formula C19H20N2O3.
MS m/z 325.11(M + H+). 1H NMR (300 MHz, CDCl3) δ 7.79–7.87 (m, 2H), 7.68–7.76 (m, 2H), 7.19–7.36
(m, 5H), 3.83–3.90 (m, 2H), 3.81 (s, 2H), 3.62–3.74 (m, 1H), 2.54–2.82 (m, 4H), 1.66–1.83 (m, 2H). 13C NMR
(75 MHz, DMSO-d6) δ 168.35, 141.02, 134.73, 132.17, 128.52, 128.37, 127.00, 123.36, 67.89, 55.33, 53.36,
35.49, 33.95.
2-(3-Hydroxy-4-((2-methoxybenzyl)amino)butyl)isoindoline-1,3-dione (10). Following the procedure A, reaction
of (2-methoxyphenyl)methanamine (0.072 mL, 0.550 mmoL) with 2-(2-(oxiran-2-yl)ethyl)isoindoline-1,3-
dione (21) (0.120 g, 0.550 mmoL) and a catalytic amount of pyridine in 4 mL n-propanol was performed.
Yield: 54 mg (27.7%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.21. MW 354.41. Formula C20H22N2O4.
MS m/z 355.15 (M + H+). 1H NMR 7.77–7.87 (m, 2H), 7.65–7.75 (m, 2H), 7.27–7.38 (m, 2H), 6.85–6.99
(m, 2H), 4.16 (d, J = 13.48 Hz, 1H), 3.99 (d, J = 13.48 Hz, 1H), 3.86–3.92 (m, 3H), 3.69–3.86 (m, 4H), 2.90
(dd, J = 12.31, 2.93 Hz, 1H), 2.66 (dd, J = 12.31, 9.96 Hz, 1H), 1.50–1.86 (m, 3H). 13C NMR (75 MHz,
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CDCl3) δ 168.36, 157.46, 134.73, 132.17, 129.35, 128.35, 128.23, 123.36, 120.48, 110.85, 67.78, 55.63, 49.04,
47.97, 35.46, 33.95.
2-(3-Hydroxy-4-((4-methoxybenzyl)amino)butyl)isoindoline-1,3-dione (11). Following the procedure A, reaction
of (4-methoxyphenyl)methanamine (0.096 mL, 0.738 mmoL) with 2-(2-(oxiran-2-yl)ethyl)isoindoline-1,3-
dione (21) (130 mg, 0.600 mmoL) and a catalytic amount of pyridine in 3 mL n-propanol was performed.
Yield: 55 mg (25.9%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.24. MW 354.41. Formula C20H22N2O4.
MS m/z 355.08 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.77–7.87 (m, 2H), 7.66–7.74 (m, 2H), 7.24
(d, J = 8.46 Hz, 2H), 6.84 (d, J = 8.46 Hz, 2H), 3.84 (t, J = 6.67 Hz, 2H), 3.66–3.79 (m, 6H), 3.35 (br.s.,
2H), 2.70 (dd, J = 11.80, 3.08 Hz, 1H), 2.58 (dd, J = 12.05, 8.72 Hz, 1H), 1.64–1.83 (m, 2H). 13C NMR
(75 MHz, CDCl3) δ 168.67, 158.93, 133.98, 132.05, 130.49, 129.67, 123.27, 113.90, 66.85, 55.23, 53.94, 52.76,
34.63, 33.78.
2-(5-(Benzylamino)-4-hydroxypentyl)isoindoline-1,3-dione (12). Following the procedure A, reaction of
phenylmethanamine (0.071 mL, 0.650 mmoL) with 2-(3-(oxiran-2-yl)propyl)isoindoline-1,3-dione (22)
(0.150 g, 0.650 mmoL) and a catalytic amount of pyridine in 4 mL n-propanol was performed. Yield: 52
mg (23.7%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.21. MW 338.41. Formula C20H22N2O3. MS m/z
339.40 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.78–7.86 (m, 2H), 7.66–7.74 (m, 2H), 7.27–7.41 (m, 5H),
3.84–3.97 (m, 2H), 3.74–3.84 (m, 1H), 3.66–3.73 (m, 2H), 3.30 (br.s., 1H), 2.77 (dd, J = 12.31, 2.93 Hz,
1H), 2.55 (dd, J = 12.02, 9.67 Hz, 1H), 1.79–1.94 (m, 1H), 1.63–1.79 (m, 1H), 1.38–1.52 (m, 2H), 1.35 (d,
J = 11.14 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 168.43, 137.05, 133.89, 132.08, 128.69, 127.82, 127.51,
123.18, 68.15, 53.86, 52.92, 37.76, 31.93, 24.81.
2-(4-Hydroxy-5-((2-methoxybenzyl)amino)pentyl)isoindoline-1,3-dione (13). Following the procedure A, reaction
of (2-methoxyphenyl)methanamine (0.085 mL, 0.650 mmol) with 2-(3-(oxiran-2-yl)propyl)isoindoline-1,3-
dione (22) (0.150 g, 0.650 mmol) and a catalytic amount of pyridine in 4 mL n-propanol was performed.
Yield: 52 mg (21.8%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.18. MW 368.43. Formula C21H24N2O3.
MS m/z 369.17 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.76–7.87 (m, 2H), 7.65–7.73 (m, 2H), 7.29–7.39
(m, 2H), 6.86–6.98 (m, 2H), 4.22 (d, J = 12.89 Hz, 1H), 4.01 (d, J = 12.89 Hz, 1H), 3.91 (s, 3H), 3.62–3.72 (m,
2H), 2.89 (dd, J = 12.31, 1.76 Hz, 1H), 2.62 (dd, J = 12.02, 10.26 Hz, 1H), 1.83 (dt, J = 9.23, 6.52 Hz, 1H),
1.58–1.75 (m, 1H), 1.31–1.44 (m, 3H), 1.23–1.30 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 168.39, 157.81,
133.88, 132.05, 131.65, 131.10, 123.17, 120.88, 119.03, 110.64, 66.10, 55.59, 52.75, 47.77, 37.63, 31.73, 24.73.
2-(6-(Benzylamino)-5-hydroxyhexyl)isoindoline-1,3-dione (14). Following the procedure A, reaction of
phenylmethanamine (0.062 mL, 0.570 mmoL) with 2-(4-(oxiran-2-yl)butyl)isoindoline-1,3-dione (23)
(0.140 g, 0.570 mmoL) and a catalytic amount of pyridine in 4 mL n-propanol was performed. Yield: 69
mg (34.1%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.19. MW 352.43. Formula C21H24N2O3. MS m/z
353.22 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.77–7.86 (m, 2H), 7.65–7.73 (m, 2H), 7.27–7.44 (m, 5H),
3.88–4.01 (m, 2H), 3.70–3.84 (m, 2H), 3.66 (t, J = 7.03 Hz, 2H), 2.79 (dd, J = 12.31, 2.93 Hz, 1H), 2.58
(dd, J = 12.02, 9.67 Hz, 1H), 1.57–1.77 (m, 2H), 1.39–1.56 (m, 3H), 1.22–1.39 (m, 2H) 13C NMR (75 MHz,
CDCl3) δ 168.42, 135.48, 133.86, 132.11, 129.09, 128.81, 128.23, 123.17, 68.03, 53.44, 52.54, 37.70, 34.31,
28.47, 22.68.
2-(5-Hydroxy-6-((2-methoxybenzyl)amino)hexyl)isoindoline-1,3-dione (15). Following the procedure A, reaction
of (2-methoxyphenyl)methanamine (0.057 mL, 0.440 mmoL) with 2-(4-(oxiran-2-yl)butyl)isoindoline-1,3-
dione (23) (0.109 g, 0.440 mmoL) and a catalytic amount of pyridine in 3 mL n-propanol was performed.
Yield: 49.8 mg (29.4%), TLC (DCM/MeOH, 9.5/0.5, v/v) Rf = 0.16. MW 382.46. Formula C22H26N2O3.
MS m/z 383.20 (M + H+). 1H NMR (300 MHz, CDCl3) δ 7.76–7.85 (m, 2H), 7.65–7.73 (m, 2H), 7.29–7.39
(m, 2H), 6.87–6.99 (m, 2H), 3.96–4.32 (m, 3H), 3.90 (s, 3H), 3.56–3.68 (m, 2H), 2.88 (dd, J = 12.31, 2.34 Hz,
1H), 2.62 (dd, J = 12.31, 9.96 Hz, 1H), 1.56–1.76 (m, 2H), 1.22–1.56 (m, 6H). 13C NMR (75 MHz, CDCl3)
δ 168.36, 157.84, 133.85, 132.08, 131.74, 131.12, 123.15, 120.88, 118.88, 110.61, 66.30, 55.56, 52.52, 47.38,
37.69, 34.10, 28.41, 22.58.
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3.2. Biological Activity
3.2.1. In Vitro Inhibition of AChE and BuChE
Inhibitory activities of the synthesized compounds against the cholinesterases were measured
using the spectrophotometric method described by Ellman et al. [23], as modified for 96-well
microplates. AChE from Electrophorus electricus (eeAChE) and BuChE from equine serum
(eqBuChE) were used. 5,5′-Dithiobis-(2-nitrobenzoic acid) (DTNB), acetylthiocholine iodide (ATC),
butyrylthiocholine iodide (BTC), and both cholinesterases were purchased from Sigma–Aldrich.
The enzymes were prepared by dissolving 500 U of each in water to give stock solutions of 5 U/mL.
eeAChE and eqBuChE were further diluted before use to a final concentration of 0.384 U/mL. In the
first step of Ellman’s method, 25 µL of the test compound (or water; i.e., blank samples) was incubated
in 0.1 M phosphate buffer (200 µL, pH = 8.0) with DTNB (20 µL; 0.0025 M) and the enzyme (20 µL;
eeAChE or eqBuChE) at a temperature of 25 ◦C. Then, after an incubation period of 5 min, 20 tµL of
ATC (0.00375 M) or BTC (0.00375 M) solutions (depending on the enzyme used) were added. After a
further 5 min, the changes in absorbance were measured at 412 nm using a microplate reader (EnSpire
Multimode; PerkinElmer, Hong Kong, China). All compounds were tested at a screening concentration
of 10 µM. Percent of inhibition was calculated from 100 − (S/B) × 100, where S and B were the
respective enzyme activities with and without the test sample, respectively. For compounds with better
than 50% inhibitory activity at 10 µM, the IC50 values were determined. To determine the IC50 value,
six different concentrations of each compound were used to obtain enzyme activities between 5%
and 95%. All reactions were performed in triplicate. The IC50 values were calculated using nonlinear
regression (GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA, 5.00)) by plotting the residual
enzyme activities against the applied inhibitor concentration.
3.2.2. In Vitro BACE-1 Inhibitory Activity
All the compounds were tested as hBACE-1 inhibitors using a PanVera’s BACE-1 fluorescence
resonance energy transfer (FRET) [24,25] Assay Kit, which includes purified baclovirus-expressed
BACE-1 and specific peptide substrate (Rh-EVNLDAEFK-quencher), based on the “Swedish” mutant
of APP. The assay was purchased from Life Technologies Polska Sp. z o.o. The analyses were carried
out according to the supplied protocol with small modifications using 384-well black microplates and
a microplate reader (EnSpire Multimode; PerkinElmer).The wavelength was optimized for 553 nm
excitation and 576 nm emission. Stock solutions of all test compounds were prepared in DMSO and
further diluted with assay buffer (50 mM sodium acetate; pH 4.5). In the first step, 10 µL of BACE-1
substrate was mixed with 10 µL of test compound (or assay buffer; i.e., blank sample), then 10 µL
of enzyme (1 U/mL) was added to start the reaction. After 60 min of incubation at 25 ◦C, 10 µL of
stop solution (2.5 M sodium acetate) was applied to stop the reaction. The fluorescence signal was
read at 576 nm. Percent of inhibition was calculated from [1 − (S60 − S0)/(C60 − C0)] × 100, where
S0 and S60 are the fluorescence intensities of the test sample (enzyme, substrate, test compound)
at the beginning of the reaction and after 60 min, respectively, while C0 and C60 are the analogical
fluorescence intensities of the blank sample (enzyme, substrate, buffer). All of the compounds were
tested at a screening concentration of 50 µM. Each compound was analyzed in triplicate. BACE-1
Inhibitor IV (Calbiochem, Merck, Nottingham, UK) was used as the reference compound.
3.2.3. Inhibition of Aβ-Aggregation
In order to investigate the inhibition of β-amyloid peptide aggregation by the compounds,
a thioflavin T-based fluorometric assay was performed [27]. Recombinant human HFIP-pretreated
Aβ1–42 peptide (Lot 2691412 and 2718332, Merck Millipore, Darmstadt, Germany) was dissolved in
DMSO to give a 75 µM stock solution. The stock solution was further diluted in HEPES buffered
solution (150 mM HEPES, pH 7.4, 150 mM NaCl) to 7.5 µM. Aβ1–42 solution was then added to the test
compounds in black-walled 96-well plate and diluted with ThT solution (final concentration of 10 µM).
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The final mixture contained 1.5 µM Aβ1–42, 10 µM of test compound, and 3% DMSO. ThT fluorescence
was measured every 300 s (excitation wavelength of 440 nm, emission wavelength of 490 nm), with the
medium continuously shaking between measurements using a 96-well microplate reader (Synergy™
H4, BioTek Instruments, Inc., Weinusky, VT, USA). The ThT emission of the Aβ1–42 began to rise after
approximately 4 h, reached a plateau after 20 h, and remained almost unchanged for an additional
28 h of incubation. The fluorescence intensities at the plateau in the absence and presence of the
test compounds were averaged, and the average fluorescence of the corresponding wells at t = 0 h
was subtracted. The Aβ1–42 aggregation inhibitory potency is expressed as the percentage inhibition
(% inh = (1 − Fi / F0) × 100%), where Fi is the increase in fluorescence of Aβ1–42 treated with the
test compound and F0 is the increase in fluorescence of Aβ1–42 alone. The percentage of inhibition is
expressed as mean ± standard deviation of at least two independent experiments; p < 0.05, statistically
different compared to control experiments (Aβ1–42 + DMSO); one-way analysis of variance (ANOVA),
followed by post hoc Bonferroni t-test (SigmaPlot v 12.0).
3.3. Molecular Modeling
All compounds prepared by the LigPrep program were docked with GOLD 5.3 (CCDC) to AChE
(PDB code 1EVE), BuChE (PDB code 1P0I) complex, and to BACE-1 (PDB code 4D8C) [37]. Each protein
was prepared using Hermes 1.7 (CCDC) [38]. All histidine residues were protonated at Nε and the
hydrogen atoms were added. The binding sites were defined as: all amino acid residues within a
radius of 10 Å from the donepezil (E20) present in the AChE, all amino acid residues within a radius
of 20 Å from the glycerol molecule (GOL) present in the active center of BuChE, and all amino acid
residues within a radius of 10 Å from the ligand (BXD) in the BACE-1 complex. Standard settings
of the genetic algorithm were applied in each docking procedure. We received 10 conformations for
each docked ligand sorted by the ChemScore (for AChE and BuChE) and the GoldScore (for BACE-1)
function value. Results of docking were visualized with PyMOL 0.99rc6 (DeLano Scientific LLC) [39].
4. Conclusions
Modification of the lead structure is a simple way to improve affinity for a selected (desired)
biological target. In the case of multi-target-directed ligands, this strategy is more complicated because
it requires optimization towards more than one target. In this study, new potential MTDLs have
been designed and synthesized based on previously obtained AChE inhibitors. The structure of
lead III (2-(5-(4-flurobenzylamino)pentyl)isoindoline-1,3-dione) was modified with expected activity
against disease-modifying and symptomatic targets. In order to introduce additional inhibitory
activity against BACE-1, we enriched the base compound by adding a hydroxyl group at position
2 of the alkyl chain, which is a common moiety occurring in BACE-1 inhibitors. Results indicate
that the presented modification leads to an overall decrease in anticholinesterase activity; however,
an inhibitory effect against BACE-1 appears. In terms of cholinesterase inhibition, the most interesting
compounds are 5 (selective inhibitor of eqBuChE) and 15 (dual action against both cholinesterases).
However, considering the multifunctional profile, the most valuable compound seems to be 12
(2-(5-(benzylamino)-4-hydroxypentyl)isoindoline-1,3-dione) with a balanced activity profile involving
inhibition of eeAChE (IC50 = 3.33 µM), hBACE-1(43.7% at 50 µM), and Aβ-aggregation (24.9% at
10 µM). Most existing multifunctional, anti-Alzheimer’s agents are cholinesterase inhibitors with some
additional properties, such as inhibition of Aµ aggregation, antioxidative action, a neuroprotective
effect, or metal chelating activity. Relatively few inhibitors of both cholinesterase and BACE-1 have
been identified thus far. Therefore, the presented results represent a promising start towards the
identification and synthesis of new active multifunctional agents.
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